GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Altman Z-Score

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Altman Z-Score

: -3.50 (As of Today)
View and export this data going back to 2021. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of -3.36 is in distress zone. This implies bankruptcy possibility in the next two years.

Ginkgo Bioworks Holdings has a Altman Z-Score of -3.50, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Ginkgo Bioworks Holdings's Altman Z-Score or its related term are showing as below:

DNA' s Altman Z-Score Range Over the Past 10 Years
Min: -3.36   Med: -1.89   Max: 12.55
Current: -3.36

During the past 5 years, Ginkgo Bioworks Holdings's highest Altman Z-Score was 12.55. The lowest was -3.36. And the median was -1.89.


Ginkgo Bioworks Holdings Altman Z-Score Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
- - 12.55 -2.00 -1.89

Ginkgo Bioworks Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.00 -2.40 -1.23 -1.42 -1.89

Competitive Comparison

For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ginkgo Bioworks Holdings Altman Z-Score Distribution

For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Ginkgo Bioworks Holdings's Altman Z-Score falls into.



Ginkgo Bioworks Holdings Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Ginkgo Bioworks Holdings's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.5031+1.4*-3.1768+3.3*-0.5362+0.6*3.2764+1.0*0.151
=-3.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $1,665.3 Mil.
Total Current Assets was $1,001.7 Mil.
Total Current Liabilities was $163.9 Mil.
Retained Earnings was $-5,290.5 Mil.
Pre-Tax Income was -211.892 + -302.913 + -173.248 + -204.887 = $-892.9 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.0 Mil.
Revenue was 34.755 + 55.43 + 80.568 + 80.702 = $251.5 Mil.
Market Cap (Today) was $1,861.6 Mil.
Total Liabilities was $568.2 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1001.749 - 163.86)/1665.342
=0.5031

X2=Retained Earnings/Total Assets
=-5290.528/1665.342
=-3.1768

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-892.94 - 0)/1665.342
=-0.5362

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=1861.607/568.19
=3.2764

X5=Revenue/Total Assets
=251.455/1665.342
=0.151

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Ginkgo Bioworks Holdings has a Altman Z-Score of -3.50 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Ginkgo Bioworks Holdings  (NYSE:DNA) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Ginkgo Bioworks Holdings Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Traded in Other Exchanges
Address
27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.
Executives
Jason R Kelly director, officer: CEO & Founder 667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk officer: Chief Financial Officer C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton 10 percent owner C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty director, 10 percent owner, officer: President, COO & Founder C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan director, officer: CEO, Chairman 1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar director C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen officer: Chief Accounting Officer C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon officer: Chief Accounting Officer C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan director ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830